ASCO Breast Cancer
Conference Coverage
Women with HER2+ metastatic breast cancer are living longer
Overall survival improved 5.6% each year among over 5,000 patients in the study.
Conference Coverage
Treating bone loss ups survival for breast cancer patients
Findings suggest a trend toward reduction in contralateral breast cancer in the treatment group.
Conference Coverage
Pembrolizumab before surgery improves survival in early triple negative breast cancer
Treatment shifts residual cancer burden to lower categories.
Conference Coverage
New treatment outperforms chemo in HER2-low breast cancer
The results may cause clinicians to reconsider how they define HER2 expression in breast cancer.
Conference Coverage
New treatment meets unmet need in breast cancer
Expert calls advance incremental, but clinically important for women with HR positive/HER2 negative breast cancer.
Conference Coverage
ctDNA spots breast cancer recurrence
Personalized surveillance technique has the potential to augment adjuvant therapy and improve long-term outcomes.
Conference Coverage
Oncologists flock to Chicago for ASCO, after 2 years online
The theme of the 2022 meeting is advancing equitable cancer care through innovation.
Latest News
Rapid update to ASCO breast cancer guidelines after OlympiA data
The American Society of Clinical Oncology (ASCO) now recommends offering 1 year of adjuvant...
Conference Coverage
DCIS: Biosignature helps guide postlumpectomy decisions
The tool shows promise for identifying those whose cancer is likely to recur despite undergoing postlumpectomy radiotherapy.
Conference Coverage
Promising HER2+/HR– breast cancer survival with de-escalated therapy
Conference Coverage
CONCERT: Better QoL but not survival with cabazitaxel in metastatic HER2– breast cancer